# Vaccines

Vaccines aim to activate a specific immune response and various peptide/protein vaccines are currently under investigation for tumor treatment. Examples include peptides derived from myeloma-associated antigens, such as mutant Wilms tumor 1 (WT 1), X-box binding protein 1 (XBP1), syndecan-1 (CD138), and CS1 (CD319).

Filter by content:

## Types
- MGUS
- Newly diagnosed multiple myeloma
- Relapsed/refractory multiple myeloma
- Smoldering multiple myeloma

## Therapeutics
- Auto-HSCT
- Carfilzomib
- Dexamethasone
- Elotuzumab
- Lenalidomide
- Melphalan
- PVX-410 Vaccines

## Congresses
- ASCO 2019
- ASH 2017
- ASH 2019
- COMy 2019
- ESH 2018

## Trials
- GEM-CESAR

## Expert Opinions
- Francesca Gay
- Irene Ghobrial
- María-Victoria Mateos
- Sagar Lonial

## Educational Resources

### Notable Articles
1. **[Smoldering multiple myeloma (SMM): an introduction to this month’s educational theme on the multiple myeloma (MM) Hub](/content/medical-information/smoldering-multiple-myeloma-smm-an-introduction-to-this-month-s-educational-theme-on-the-multiple-myeloma-mm-hub/index.html)**  
   Starting July 2019, the Multiple Myeloma (MM) Hub will be featuring articles centered around an...
2. **[David Avignan | ESH MM 2018 | Vaccines in myeloma](/content/medical-information/david-avignan-or-esh-mm-2018-or-vaccines-in-myeloma/index.html)**  
   David Avignan comments on the challenges of creating specific, yet broad-targeting, vaccines as...
3. **[PVX-410 vaccine alone or with lenalidomide for patients with smoldering multiple myeloma](/content/medical-information/pvx-410-vaccine-alone-or-with-lenalidomide-for-patients-with-smoldering-multiple-myeloma/index.html)**  
   PVX-410 is safe and can increase immunogenicity in a patient population with smoldering myeloma...

## All Therapeutics

### Antibody recruiting molecules
- [BHV-1100](/content/therapeutics/antibody-recruiting-molecules/bhv-1100/index.html)

### Antibody therapy
- [ALLO-647](/content/therapeutics/antibody-therapy/allo-647/index.html)
- [Anselamimab](/content/therapeutics/antibody-therapy/anselamimab/index.html)
- [AO-176](/content/therapeutics/antibody-therapy/ao-176/index.html)
- [Birtamimab](/content/therapeutics/antibody-therapy/birtamimab/index.html)
- [CAEL-101](/content/therapeutics/antibody-therapy/cael-101/index.html)
- [Daratumumab](/content/therapeutics/antibody-therapy/daratumumab/index.html)
- [Denosumab](/content/therapeutics/antibody-therapy/denosumab/index.html)

### BCL-2 inhibitors
- [Venetoclax](/content/therapeutics/bcl-2-inhibitors/venetoclax/index.html)

### Biological therapy
- [Anakinra](/content/therapeutics/biological-therapy/anakinra/index.html)

### Chemotherapy
- [Bendamustine](/content/therapeutics/chemotherapy/bendamustine/index.html)
- [Busulfan](/content/therapeutics/chemotherapy/busulfan/index.html)
- [Carmustine](/content/therapeutics/chemotherapy/carmustine/index.html)

### T-cell engagers
- [Alnuctamab](/content/therapeutics/t-cell-engagers/alnuctamab/index.html)
- [AMG 420](/content/therapeutics/t-cell-engagers/amg-420/index.html)

### Vaccines
- [PVX-410](/content/therapeutics/vaccines/pvx-410/index.html)